Markets
SYN

Synthetic Biologics Tanks on Unfavorable Trimesta Data

Synthetic Biologics Inc. 's SYN shares plunged 14.1% to a new 52-week low after the company reported unfavorable results from an independent third-party analysis of a phase II study on Trimesta for the treatment of women with relapsing-remitting multiple sclerosis (RRMS).

Data from the analyses (both clinical and magnetic resonance imaging) demonstrated statistically insignificant differences between the group treated with Trimesta in combination with Teva Pharmaceutical Industries Limited's TEVA Copaxone, and the group treated with Copaxone plus placebo, at either 12 or 24 months.

Based on these unfavorable data, Synthetic Biologics plans to terminate its license and clinical trial agreements related to Trimesta with the Regents of the University of California.

We note that the market for multiple sclerosis (MS) is already quite crowded with several drugs including Avonex, Betaseron, Plegridy, and Tecfidera among others.

Meanwhile, Trimesta is also being evaluated in a phase II study for the treatment of cognitive dysfunction in female MS patients.

Synthetic Biologics stated that it now intends to direct its resources toward the development of two phase II gut microbiome programs, both of which have demonstrated positive top-line results.

Last month, the company reported positive results from the second phase II study on SYN-010 for the treatment of irritable bowel syndrome with constipation. The company expects to present detailed results from the phase II study and request for an end-of-phase II meeting with the FDA in the first half of 2016.

Synthetic Biologics currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector are Celgene Corporation CELG and Ligand Pharmaceuticals Incorporated LGND , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CELGENE CORP (CELG): Free Stock Analysis Report

LIGAND PHARMA-B (LGND): Free Stock Analysis Report

SYNTHETIC BIOLG (SYN): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SYN LGND TEVA

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More